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Abstract: Administered by an oral route, Furosemide (FUR), a diuretic used in several edematous
states and hypertension, presents bioavailability problems, reported as a consequence of an erratic
gastrointestinal absorption due to various existing polymorphic forms and low and pH-dependent
solubility. A mucoadhesive sublingual fast-dissolving FUR based film has been developed and
evaluated in order to optimize the bioavailability of FUR by increasing solubility and guaranteeing
a good dissolution reproducibility. The Differential Scanning Calorimetry (DSC) analyses confirmed
that the film prepared using the solvent casting method entrapped FUR in the amorphous state.
As a solid dispersion, FUR increases its solubility up to 28.36 mg/mL. Drug content, thickness, and
weight uniformity of film were also evaluated. The measured Young’s Modulus, yield strength, and
relative elongation of break percentage (EB%) allowed for the classification of the drug-loaded film as
an elastomer. Mucoadhesive strength tests showed that the force to detach film from mucosa grew
exponentially with increasing contact time up to 7667 N/m2. FUR was quickly discharged from
the film following a trend well fitted with the Weibull kinetic model. When applied on sublingual
mucosa, the new formulation produced a massive drug flux in the systemic compartment. Overall,
the proposed sublingual film enhances drug solubility and absorption, allowing for the prediction of
a rapid onset of action and reproducible bioavailability in its clinical application.
Keywords: mucoadhesive film; sublingual absorption; amorphous solid dispersion; furosemide
bioavailability; transmucosal delivery
1. Introduction
Hypertensive emergencies and hypertensive urgencies are commonly encountered by a wide
variety of clinicians. Prompt recognition, evaluation, and appropriate treatment of these conditions are
crucial to prevent permanent organ damage [1].
Furosemide (FUR) is a loop diuretic used orally in the treatment of edematous states associated
with cardiac, renal, and hepatic failures and in the treatment of hypertension [2]. The usual dosage
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is 40–120 mg/day. For the treatment of mild cases of edema, doses as low as 20 mg can be effective,
whereas for severe cases, doses as high as 600 mg/day may be required [3].
Data on solubility, oral absorption, and permeability are sufficiently exhaustive to classify FUR
into Class IV of the Biopharmaceutics Classification System. Due to the carboxyl and sulfonamidic
groups in the structure, with pKa of 3.8 and 9.6, respectively [4], FUR shows a very low solubility
in water that increases as a function of pH from 0.01 mg/mL at pH 2 to 1.9 mg/mL at pH 7.4 [5],
determining a higher absorption in the gastric rather than intestinal tracts. A erratic bioavailability
of about 37–51% and large inter- and intra-subject variabilities in rate and the extent of absorption
were also reported [6]. Absorption following oral administration is influenced by the dosage form,
underlying disease processes, and by the presence of food. The intra-subject variability was thought to
be mainly dependent on the absorption process, since repeated intravenous (i.v.) doses showed only
marginal variability [7].
The bioavailability problems, reported as consequences of variable and erratic gastrointestinal
absorption, are probably due to the low and pH-dependent solubility together with various existing
polymorphic forms of FUR. [8]. Indeed, FUR presents different polymorphic forms: four are true
polymorphs (I, II, III, IV), two are solvates (IV-DMSO and V-dioxane) and one is an amorphous
form [9,10]. It is well known that different polymorphic forms of an active administered in the oral or
topical form can modify many properties like solubility, stability, color, compressibility, flowability,
and workability and as a consequence can cause differences in bioavailability, toxicological safety,
clinical effectiveness, and productive efficiency [11].
Different approaches have been proposed to enhance FUR absorption and bioavailability such
as co-crystallisation [12,13], solid dispersion [14], microemulsification [15], and supramolecular
complexes formation [16].
Oral mucosal drug delivery is an alternative and promising method of systemic delivery which
offers several advantages [17,18]. The oral mucosa is highly vascularized; for this reason, drugs that
are absorbed through it directly enter the systemic circulation, bypassing the gastrointestinal tract and
first-pass metabolism in the liver. [19]. When sublingual mucosa administration is chosen, a rapid onset
of action results via a more comfortable and convenient delivery route than the intravenous route. [20].
Additional advantages include an improved bioavailability for certain drugs and an easy access to the
absorption sites so that the delivery system can be applied and removed easily [21,22]. Fast dissolving
oral film, in particular when placed in the oral cavity, rapidly disintegrates and dissolves to release the
medication without chewing and intake of water [23,24]. It gives quick absorption and bioavailability
comparable to intravenous administration.
Bioadhesive sublingual formulations [25], such as tablets [26], patches, and films, have been
developed using mucoadhesive polymers that can establish a strong adhesive contact with the
mucosa, allowing for an increase in residence time of the delivery system and optimizing drug
bioavailability [19,27]. The release kinetics of a given drug from a polymeric matrix could be governed
predominantly by the polymer morphology and excipients present in the system [28].
Furthermore, a comparative study on pharmacokinetics and pharmacodynamics of FUR after
administration of the same tablets for both sublingual and oral routes, using the i.v. route as control,
has been reported. The authors concluded that the insignificant differences observed between oral and
sublingual routes were due to the slow disintegration of the oral tablet that produces a variable dose
fraction swallowed in the sublingual environment and that a dosage form suitably formulated to be
applied on the sublingual mucosa would improve the bioavailability of FUR [29].
As a consequence, the aim of this work is the design of an adequate new formulation capable of
improving the pharmacokinetics of FUR when administered sublingually.
In this study, a mucoadhesive sublingual fast-dissolving film loaded with amorphous FUR
has been developed. The formulation was designed in order to optimize the bioavailability of
FUR by increasing solubility and guarantying good dissolution profile reproducibility and massive
transmucosal absorption.
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2. Experimental
2.1. Materials
FUR, Ph. Eur. grade, was purchased from Galeno srl (Carmignano, PO, Italy). Methacrylic
acid-methyl methacrylate copolymer (Eudragit® L-100) was kindly supplied by Rofarma (Milan,
Italy). Polyvinylpyrrolidone K-90 (PVP K-90), Sorbitol, Agar, Triethanolamine (TEA), and NaOH were
purchased from Sigma-Aldrich (Milano, Italy). Propylene glycol was purchased from Farmalabor
(Canosa di Puglia, Italy).
Buffer pH 6.8 solution simulating saliva was prepared using NaCl, KCl, KSCN, KH2PO4, Urea,
Na2SO4 10H2O, NH4Cl, CaCl2·2H2O, and NaHCO3 in distilled water according to Gal et al. [30].
A total of 6 mM phosphate buffered saline (PBS), Ca2+, and Mg2+ free solution, simulating pH 7.4
plasma, was prepared by dissolving KH2PO4, anhydrous Na2HPO4, and NaCl in distilled water.
A 0.9% saline solution was prepared by dissolving NaCl in distilled water.
All chemicals and solvents of analytical grade were purchased from VWR International (Leuven,
Belgium) and used without further purification. Porcine mucosae were kindly supplied by the
Municipal Slaughterhouse of Villabate (Palermo, Italy).
2.2. Methods
2.2.1. Preparation of Mucoadhesive Film
TEA (450 mg) and FUR (600 mg) were added to an aqueous solution (10 mL) of propylene glycol
(150 mg), Sorbitol (80 mg), and PVP-K90 (40 mg), and the resulting solution was stirred until complete
dissolution. Then, Eudragit L100® (1 g) and NaOH 1 M (5 mL) were added to the solution until a fluid,
transparent, and homogeneous viscous solution was formed. The mixture was poured into a silicon
mold having an area of 20.25 cm2 and dried in an oven at 40 ◦C for 48 h. The so formed films (plain
patches) were then left to equilibrate at room temperature and humidity for 24 h, checked for any
imperfections or air bubbles, and cut by a biopsy punch into disks 8.0 mm in diameter (area 0.5 cm2).
The samples were packed in polyethylene bags, heat-sealed, and stored at room temperature in a glass
container to maintain the integrity and elasticity of the films.
2.2.2. Film Weight, Thickness, and Drug Load Uniformity
Five disks from each batch were randomly cut and weighed. The diameter and thickness
were measured with a vernier caliper and an analog micrometer (Mitutoyo Italiana SRL, Milano,
Italy), respectively.
Drug content was estimated by dissolving a randomly selected disk, by sonication, into a 200 mL
flask filled to volume by distilled water. The amount of FUR released from the film was measured
spectrophotometrically (UV/Vis Shimadzu model 1700 instrument, Japan) at λmax = 331 nm, (linearity
range 0.005–0.1 mg/mL, E1%water = 0.158, corr. coeff. 0.999).
The uniformity of batches was evaluated by calculating the averages and standard deviations for
all the considered parameters.
2.2.3. Differential Scanning Calorimetry (DSC)
Differential Calorimetric Analysis was performed on the patches and on their individual
components (sample weight was approx. 8 mg) by a Perkin Elmer Jade calorimeter with a temperature
ramp from 30 ◦C to about 250 ◦C at 10 ◦C/min, under nitrogen flow.
2.2.4. Attenuated Total Reflectance (ATR)
ATR-FTIR spectra were recorded on a Fourier Transform Infrared Spectrometer (FTIR) (Spectrum
Two FTIR spectrometer, Perkin Elmer) equipped with an ATR unit plug-and-play with a diamond crystal
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for surface analysis. Spectra were obtained by accumulation of 32 scans between 4000 and 450 cm−1 at
4.0 cm−1 resolution and rationed to the appropriate background spectra.
2.2.5. Mechanical Tests
Mechanical properties of films were evaluated using an Instron Universal Testing instrument
(model 3365 equipped with 8500 digital control, Instron, Norwood, MA, USA) with a 1 kg load cell.
A specimen with dimensions of 10 × 60 × (0.9 ± 0.12) mm was held between two grips covered by
a felt pad to prevent slippage and positioned at a distance of 2 cm. A tensile test was performed at
a rate of 100 mm/min. Tensile strength and elongation at break were measured. Reported data are
averaged on the results of a minimum of eight specimens.
2.2.6. Surface pH of Film
Randomly selected film disks were swollen for 2 h on the surface of an agar plate, prepared by
dissolving 2% (wt/vol) agar in warmed simulated saliva (pH 6.8) under stirring and then pouring the
solution into a Petri dish until it gelled at room temperature.
Surface pH was measured using a pH meter (HI 2211 pH/ORP Meter, Hanna Instrument,
Woonsocket, RI, USA) by placing pH probe in close contact with the wetted patch surface. The surface
pH study was carried out by selecting three disks.
2.2.7. Evaluation of the Solubility of FUR Entrapped into Film
In 1 mL of a buffer solution simulating saliva at pH 6.8, at 25 ± 0.1 ◦C, under stirring, small
amounts of free FUR were added until saturation. The suspension was kept under continuous stirring
for 1 h, and after the equilibrium was reached, the remaining solid FUR was removed by centrifugation
followed by filtration through a 0.45 µm membrane filter (Merk Millipore, Merck S.p.a., Vimodrone
(MI), Italy). The clear solution was suitably diluted (1:100) and analyzed by a UV-Vis spectrophotometer
at λmax = 331 nm using the appropriate blank and calibration curve (linearity range 0.005–0.1 mg/mL,
E1%salivapH6.8 = 0.156, corr. coeff. 0.999).
The same experimental protocol was used in order to evaluate the solubility of FUR incorporated
into the mucoadhesive film. Three disks, 8.0 mm in diameter, containing 11.5 mg of FUR each, were
solubilized in 1 mL of buffer to simulate saliva as previously described. These suspensions were then
sonicated at several time intervals, and after the equilibrium was reached, the remaining solid material
was removed by filtration through a 0.45 µm membrane filter (Merk Millipore, Merck S.p.a., Vimodrone
(MI), Italy). The clear solution was then analyzed. The analyses were conducted in triplicate.
2.2.8. Ex Vivo Mucoadhesion Strength Measurement
To perform the ex vivo mucoadhesive strength evaluation of the prepared film disks, the
modified two-armed physical balance method was used [31]. Porcine buccal mucosa excised from just
slaughtered pigs was used as model tissue and handled without any pre-treatment. A piece of mucosa
was glued with the aid of cyanoacrylate resin (Super Attak Loctite®, Henkel Italia Srl, Milan, Italy) on
a glass support and kept in a vessel placed in a thermostatic bath at 37 ◦C ± 1◦C. The patch was fixed
at the lower side of a rubber stopper with an adhesive and attached to the balance pan. Before starting
the measurements, the mucosal tissue was wetted with 50 µL of simulated salivary fluid and then the
patch was placed on the tissues so it just touched the mucosal surface and a light force with a fingertip
was applied for 20 s. A temperature of 37 ◦C ± 1 ◦C was maintained throughout the experiment. The
measurements started 5, 10, 15, and 20 min after application, thus allowing for different time contacts.
The adhesive strength expressed as the mass (g) required to detach the film from mucosal surface was
calculated according to the equation:
Force of adhesion (N) = (g × 9.81)/1000
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Then, detachment forces were calculated as:
Detachment force (N/m2) = Force of adhesion (N)/Surface area (m2)
The maximum adhesive force was determined as the average of the three measurements (n = 3).
2.2.9. Swelling and Radial Erosion Tests
A swelling test was conducted by placing a dry film disk (0.5 cm2 of area) on a glass support into
an analytical balance and weighed. Then, 0.1 mL of artificial saliva at pH 6.8 were added on the disk
every 5 min for 50 min. At every time interval, after removal of the excess water with a filter paper,
the weight of the wet disk was assessed. The test was performed on one disk of six different batches.
Results were reported as means ± SD (n = 6; p < 0.05).
The swelling degree (SD) was calculated using the following equation:
SD% = (Ws −Wd)/Wd × 100
where Ws corresponds to the hydrated weight of the sample and Wd represents the sample dry weight.
Furthermore, a disk was placed on a glass positioned on graph paper. The experiments were
started by placing 0.2 mL of simulated saliva (pH 6.8, 37 ◦C) on the disk and adding 0.1 mL of saliva
every 5 min, for the first 15 min, and then every 15 min. At every time interval, a photograph was
taken to evaluate any change in the disk’s morphology.
2.2.10. Drug Release Studies
Drug release in buffer solution simulating saliva was assessed using the flow through system
previously described [32]. Briefly, the system consists of a container for the buffer solution simulating
saliva (100 mL) from which the liquid is forced into a Plexiglass release chamber. The flow rate of
saliva was controlled by a peristaltic pump (Bio-Rad Econo Pump, Hercules, CA, USA) and maintained
constant at 0.5 mL/min. In the chamber, the salivary layer wetting the sides of the disk was 0.1 mm
thick. The temperature was controlled by submerging the chamber and the container in a thermostatic
bath (37 ± 0.1 ◦C). The drug amount in the solution coming out from the release chamber was then
quantitatively determined by UV analysis using the appropriate blank and calibration curve. Results
were averaged on six disks from six different batches of film. Every experiment was considered at its
end when the complete dissolution of the disk occurred and the amount of drug released matched
the original drug content of the disk. Release data were elaborated using Curve Expert v.1.4 and
Kaleidagraph v.3.5 software and fitted to the equations applied in release studies from matrix systems.
Linear or non-linear least squares fitting methods were used to determine the optimum values for the
parameters present in each equation. Fittings were validated by using χ2. A p value less than 0.05 was
considered to be statistically significant.
2.2.11. Permeation Study of FUR Released from the Film through Porcine Sublingual Mucosa
Mucosal specimens consisted of tissue removed from the ventral surface of the tongue of
freshly slaughtered domestic pigs. Specimens were prepared as described previously [17]. Briefly,
specimens, used within 2 h from animal sacrifice, were dipped for approximately 1 min in saline
solution previously warmed to 60 ◦C; the connective tissue was then carefully peeled off from the
mucosa (slides 150 ± 25 µm thick) to obtain the heat-separated epithelium along with the intact
basal lamina. The thickness was measured using a digital micrometer. Before the beginning of
the experiments, specimens were equilibrated in phosphate buffered saline pH 7.4 (PBS) for about
3 h at room temperature to remove biological matter which could interfere with drug analyses.
The equilibration medium was replaced with fresh PBS every 15 min.
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Appropriate sections of mucosa were mounted in vertical jacketed, Franz type diffusion cells
(Permeagear, flat flange joint, 9 mm orifice diameter, 15 mL acceptor volume, SES GmbH—Analysesysteme,
Bechenheim, Germany) used as a two compartment open model. Tissue disks (12 mm diameter) were
equilibrated for 1 h at 37± 0.1 ◦C adding PBS in both the donor and the acceptor compartment. This step
was followed by the removal of PBS from the donor compartment and replacement with one patch
(8 mm of diameter) in 0.4 mL of simulated saliva applied to the apical side of the membrane. At regular
time intervals (30 min), samples (0.5 mL) were withdrawn from the acceptor compartment and the
sample volume was taken out and replaced with fresh fluid. Each experiment was carried out at
37 ± 0.1 ◦C for 6 h and repeated six times using different fractions of the same portion of tissue.
The permeated FUR was determined by UV analysis using the appropriate blank and calibration curve
(linearity range 0.005–0.1 mg/mL, E1%PBSpH7.4 = 0.152, corr. coeff. 0.999). At testing concentrations,
PBS, artificial saliva, and formulation components do not interfere with FUR quantification.
Drug flux (Js) through the mucosal membrane was calculated at the steady state per unit area by
linear regression analysis of permeation data following the relationship Js = Q/At (mg/cm2 h), where
Q is the amount of the drug which passes through the cell layers into the acceptor compartment, A is
the active cross-sectional area available for diffusion (0.636 cm2), and t is the time of exposure (h).
The permeability coefficient (Kp) was then calculated according to the equation Kp = Js/Cd (cm/h),
where Cd is the drug concentration in the donor compartment (mg cm−3).
The analyses were performed on two disks of six different batches. Results were reported as
means ± SD (n = 12; p < 0.05).
3. Results and Discussion
3.1. Film Formulation
Because of low costs and ease of production, one of the most common approaches to get delivery
systems with suitable drug release is to embed the drug in an adequate matrix. The film as matrix
system is also considered the most suitable in order to obtain a solid dispersion of drugs in their
amorphous form. In particular, formulation of a bioerodible mucoadhesive film in which FUR was
homogenously dispersed has been designed with the objective of improving drug bioavailability by
an adequate delivery throughout the mucosa.
Therefore, a readily water-soluble polymer such as Eudragit® L-100 was chosen for the
formulation as the matrixing polymer, together with PVP-K90 for conferring mucoadhesive
properties. Eudragit® L-100 (Methacrylic Acid Copolymer Type A USP/NF, Methacrylic Acid—Methyl
Methacrylate Copolymer 1:1 Ph. Eur.) is a biocompatible, mucoadhesive anionic polymer. Its solubility
is closely influenced by pH, and specifically, increases for pH values above 6. This polymer, when
dispersed in the aqueous mixture containing all the formulation components, confers on the mixture a
low viscosity, which is useful for pouring and homogeneously distributing it into the mold, without
loss of product. When dried, Eudragit® L-100 is able to maintain FUR in its amorphous form and is
useful for preparing drug loaded films that ensure a fast release of the drug.
The characteristics of flexibility and softness of the films have been conferred by the introduction
in the formulation of wetting agents and plasticizers [33]; in particular, Sorbitol and Propylene Glycol
are chosen for their ability to retain water within the film and for their inhibitory activity on bacterial
growth especially when they are in association.
The quantitative composition of films has been selected on the basis of our previous experiences [34].
Films with different matrix component ratios have been tested to select the composition with the highest
FUR loading capacity and adequate characteristics of mucoadhesion and drug discharge.
Mucoadhesive sublingual films of FUR have been prepared by the solvent casting method.
The method is simple, inexpensive, and does not imply the use of organic solvents. The method
has been the most appropriate to obtain a solid dispersion of drug in a matrix system with a high
reproducibility of results.
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3.2. Film Weight, Thickness, and Drug Load Uniformity
The reproducibility of the films preparation has been assessed by measuring the average weight
(48.50 ± 1.46 mg), thickness (0.750 ± 0.022 mm), drug content (11.53 ± 0.43 mg), and surface pH
(7.2–7.4) of disks (area 0.5 cm2) from different batches. All data are in accordance with the requirements
of the Italian Pharmacopoeia [FU XII ed] and confirm high product reproducibility.
3.3. Differential Scanning Calorimetry Analysis
Drug-polymer interactions were investigated using differential scanning calorimetry (DSC).
Thermograms of the single components of the film and their mixtures in the film have been recorded.
FUR thermograms show a small peak at 219 ◦C characteristic of the onset of drug melting. This peak is
followed by a sharp exothermic peak at 220 ◦C attributable to drug decomposition that takes place
upon melting [35]. The thermogram of sorbitol shows a typical sharp melting peak at about 100 ◦C,
while Eudragit presents two endothermic peaks, at 66 and 220 ◦C, attributable to unbound water
and to the condensation in anhydride, respectively. PVP is an amorphous polymer and the only
feature in its thermogram is associated with the evaporation of absorbed water. The thermogram of
the FUR-loaded film (named “Film” in Figure 1) shows a group of endothermic peaks that can be
attributed to the melting of sorbitol domains and a shallow and broad endothermic peak remnant
of FUR degradation. This last evidence supports the theory that the drug is embedded within the
polymer matrix mostly in the amorphous form. The disappearance of Eudragit peaks, when it is in
the form of the film together with the other components, suggests that the film forming process has
removed the water, and condensation reactions are impeded or shifted to higher temperatures.
Pharmaceutics 2017, 9, 22  7 of 15 
 
3.3. Differential Scanning Calorimetry Analysis 
Drug-polymer inter ctions were investigated using differential scanning calorimetry (DSC). 
Thermograms of the single components of the film and their mixtures in the film have been 
recorded. FUR thermograms show a small peak at 219 °C characteristic of the onset of drug melting. 
This peak is followed by a sharp exothermic peak at 220 °C attributable to drug decomposition that 
takes place upon melting [35]. The thermogram of sorbitol shows a typical sharp melting peak at 
about 100 °C, while Eudragit presents two endothermic peaks, at 66 and 220 °C, attributable to 
unbound water and to the condensation in anhydride, respectively. PVP is an amorphous polymer 
and the only feature in its thermogram is associated with the evaporation of absorbed water. The 
thermogram of the FUR-loaded film (named “Film” in Figure 1) shows a group of endothermic 
peaks that can be attributed to the melting of sorbitol domains and a shallow and broad endothermic 
peak remnant of FUR degradation. This last evidence supports the theory that the drug is embedded 
within the polymer matrix mostly in the amorphous form. The disappearance of Eudragit peaks, 
when it is in the form of the film together with the other components, suggests that the film forming 
process has removed the water, and condensation reactions are impeded or shifted to higher 
temperatures. 
 
Figure 1. Differential Scanning Calorimetry (DSC) thermograms of the Furosemide (FUR)-loaded 
film and of all the individual components present in the film. 
3.4. Attenuated Total Reflectance (ATR) 
The formation of FUR-TEA salt was verified through ATR-FTIR spectroscopy. Spectra of FUR, 
FUR-TEA salt, unloaded film, and film loaded with FUR are shown in Figure 2a,b. In the spectra of 
FUR-TEA and film loaded with FUR, a sharp peak at 1610 cm−1, associated with the carbonyl 
stretching of the carboxylate anion (–COO−), is present (this peak is absent in the unloaded film) 
together with a shift from 1141 cm−1 to 1159 cm−1 due to the stretching of the C–N band, indicating 
that FUR is entrapped in the film as triethanolamine salt [36]. 
T (°C)
50 100 150 200 250
H
ea
t f
lo
w
/w
ei
gh
t (
W
/m
g)
( E
nd
o 
up
)
FUR
PVP K-90
Sorbitol
Eudragit L-100
Film 
Figure 1. Differential Scanning Calorimetry (DSC) thermograms of the Furosemide (FUR)-loaded film
and of all the individual components present in the film.
3.4. Attenuated Total Reflectance (ATR)
The formation of FUR-TEA salt was verified through ATR-FTIR spectroscopy. Spectra of FUR,
FUR-TEA salt, unloaded film, and film loaded with FUR are shown in Figure 2a,b. In the spectra
of FUR-TEA and film loaded with FUR, a sharp peak at 1610 cm−1, associated with the carbonyl
stretching of the carboxylate anion (–COO−), is present (this peak is absent in the unloaded film)
together with a shift from 1141 cm−1 to 1159 cm−1 due to the stretching of the C–N band, indicating
that FUR is entrapped in the film as triethanolamine salt [36].
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3.5. Mechanical Tests
Young’s modulus (E), yield strength (YS), and elongation at break (EB) are parameters that provide
an indication of the strength and elasticity of the patch and characterize the mechanical performance
of the film. These parameters are useful to evaluate the manageability of the film, which has to be
handled by patients without breaki g. It is suggested that a suitable buccal patch should have a
relatively high YS and EB [37,38]. The me sured Young’s Modulus was 70.22 ± 7.7 MPa, the yield
strength was 5.3 ± 0.55 MPa, nd the relative EB% was 259 ± 0.85%. The drug-loaded film can be
classified as an elastomer [39].
3.6. Surface pH
T e surf ce pH of the films ranged from 6.71 to 6.93. Since the detec ed pH value is compatible
with the oral cavity, there will not be any kind of irritation to the mucosal tissue.
3.7. Solubility Test
The assessment of solubility in simulated saliv at pH 6.8 showed that FUR disso ves o a max mum
of 3.18 mg/mL. When the FUR was incorporated in the matrix film its solubility significantly increased
up to 28.36 mg/mL, approximately nine-fold higher than the value obtained for the free FUR.
3.8. Ex Vivo Mucoadhesion Strength Measurement
The mucoadhesive properties of sublingual fil are of great i portance as they influence the
ability of the dosage form to be retained at the site of action, in inti ate contact with the absorption
membrane. Ex vivo mucoadhesion strength measurements were conducted with a modified two-armed
physical balance. It also evaluated the variation in adhesive strength as a function of contact time.
The obtained results (Table 1) are expressed as force of adhesion and detachment force, whose
equations were previously described.
Table 1. Force of adhesion and detachment force of the patch after different contact time on porcine
buccal mucosa (n = 3).
Contact Time (min) For esion (N) D tachm nt Force (N/m2)
5 0.098 1960
10 0.1196 2392
15 0.2242 4485
20 0.3834 7667
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The mucoadhesive force grew with increasing contact time of the patch and the hydration of the
latter. In particular, by increasing the time contact between the patch and mucosa, an exponential
increase of the forces required to detach the patch were observed (Figure 3).
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Figure 3. Exponential trend of detachment force of the patch as a function of contact time on porcine
buccal mucosa.
3.9. Swelling and Radial Erosion Tests
The radial erosion test was carried out in order to measure the surface area of the sublingual cavity
which is effectively covered by the film when dissolution occurs. The radial erosion test showed that,
after an initial swelling of the film that occurs in the first 10 min due to the absorption of saliva, the
disk undergoes rapid erosion and loss of weight until the total dissolution, in about 90 min (Figure 4).
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The data related to the weight variation showed that the weight of the disk increases in the first
25 min-interval due to the absorption of saliva and the consequent swelling. After that time, however,
the weight decreases due to the dissolution of the dosage form and the removal of the solution of the
drug (Figure 5).
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Figure 5. Swelling index measured as percent of weight increased vs. time. Values are presented as
means ± SD (n = 6).
These data indicate that the film absorbs the saliva which is useful for the drug dissolution, but
the swelling of the film is not so great as to cause discomfort for the patient.
3.10. Drug Release Studies
Usually, drug release from tablets is studied according to the official pharmacopoeias. Current
test methods require large volumes of dissolution medium and are operated under sink or pseudo-sink
conditions. These methods do not simulate the conditions prevailing in buccal environment where
small amounts of liquid exist; non-sink conditions are more appropriate for describing the behavior
of medications. Indeed, for buccal dosage forms, an initial fast release cannot be measured with
the existing official methods, and in vitro dissolution tests should be performed in small volumes of
dissolution medium. For these reasons, release tests were performed using a flow through cell
system able to simulate the sublingual conditions, in particular, the saliva turnover in the oral
environment [34,40]. This study, assessing the drug release from the dosage form when exposed
to small volumes of fresh salivary fluid that is continuously replaced, showed that FUR is discharged
from film quickly; in particular, about 80% of FUR was released from the dosage form within 60 min.
Experimental results were reported in Figure 6.
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To understand the mechanism of drug discharge, the most common models (zero order,
exponential, Higuchi, power law, and Weibull) used in dissolution analysis were curve fitted to
our experimental data, expressed as mean of dose fraction released versus time (Table 2).
Table 2. Mathematical models fitted to experimental release curve.
Model Equation Correlation Coefficient Standard Error
Zero order * Qt = Q0 + K0t 0.99714 0.01565
First order * Qt = Q0 exp−Kt 0.97091 0.04961
Higuchi *
Mt
M∞
= k
√
t 0.84868 0.10737
Korsmeyer–Peppas *
Mt
M∞
= atn 0.99864 0.01078
Weibull **
Mt
M∞
= 1− exp(−atb) 0.99955 0.00931
* fitted with the first 60% of the release data; ** fitted with the entire set of data
The best fit was obtained using the Weibull function (Equation (1)), characterized by an S-shaped
trend with upward curvature followed by a flattening [41].
Mt
M∞
= 1− exp(−atb) (1)
where a and b are constants.
By fitting to the entire set of data with the Equation (1), the a and b parameters resulted in
9.8 × 10−4 ± 0.56 × 10−4 and 1.75 ± 0.0146, respectively. The best fit was confirmed by R value
(0.99955), standard error (0.00931), χ2 value (0.003552), and analysis of residuals.
This behavior indicated that a complex mechanism governs the dissolution process, highlighted
by b higher than 1. The drug diffusion through the matrix network depends on the polymer/drug’s
physical and chemical characteristics. Probably, the relatively low solubility of FUR plays a role in the
dissolution process and in the release kinetics along with other release mechanisms [42].
3.11. Permeation Study of FUR Released from the Film through Porcine Sublingual Mucosa
The ability of FUR discharged from the matrix film to cross the sublingual mucosa and reach
the systemic circulation has been analyzed by performing ex vivo permeation studies using vertical
Franz type diffusion cells and porcine sublingual mucosa as the most useful model to simulate human
epithelium [43].
Figure 7 shows drug movement from the patch to the serosal side of porcine tissue, expressed as
cumulative amount of permeated FUR versus time.
Extrapolating the flux (Js) per unit area of FUR through the mucosal membrane at the steady state
showed that the new dosage form applied on porcine sublingual mucosa for six hours produced a
massive input of FUR in the acceptor compartment with a drug flux (Js) of 1.2211 ± 0.1115 mg/cm2 h
(R = 0.9981) and permeability coefficient (Kp) of 0.05309 ± 0.00485 cm/h.
Considering that in our experiments the drug release occurred from one side of the patch adhered
to the mucosa and in in vivo conditions each patch is in contact with both the floor of the mouth and
the ventral surface of the tongue, a patch of 1 cm2 produces a drug flux of about 2.5 mg/cm2 h.
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Figure 7. Plot of cumulative amount of FUR permeated across porcine sublingual mucosa vs. time
from a patch (0.5 cm2) soaked with simulated saliva. Values are presented as means ± SD (n = 12).
A sublingual drug delivery system with optimal performance should release drug amounts
adequate to reach effective plasma levels. These levels can be achieved when the rate of drug entry in
the systemic circulation is equal or greater than the rate of drug disappearance from the blood. Drug
declining follows a first order kinetic equation and is equal to the product of the plasma concentration
(Cp) with the first order rate constant of elimination (Ke). In turn, Ke can be calculated by the biological
half-life of the drug. In other words:
Drug input rate = Drug output rate = Cp × Ke
where Ke = 0.693/t1/2.
Taking into account the pharmacokinetic parameters of FUR, after oral administration of 20 mg of
FUR tablets [29] (t1/2 about 1.9 h; volume of distribution Vd about 14 L; Cmax = 552 ng/mL), the rate of
FUR elimination was calculated (Ve = Cp × Ke) as 201 µg·L·h−1 and the amount of FUR that should
reach the systemic circulation to obtain drug levels comparable to per os administration was predicted
as 2.8 mg/h (Vd × Ve) Therefore, on the basis of pharmacokinetics literature data, it is possible to
hypothesize that by administration of a 1 cm2 patch therapeutic plasma levels of FUR can be achieved.
Furthermore, due to both the drug release results and radial swelling tests, we can highlight
that within 60 min the dosage form dissolved, leaving a highly concentrated drug solution that can
be spread over a wider surface of the floor of the mouth, increasing the surface area available for
absorption and, consequently, reducing the time to achieve therapeutic concentration.
The calculated plasma levels of the drug, reached by means of the designed drug delivery system,
indicate the patch’s suitability for use in the management of hypertension. Nevertheless, the in vitro
approach for new dosage forms has inherent weaknesses since it cannot capture all the differences
that the in vivo environment can offer, being affected by several parameters, i.e., salivary turnover, pH,
health state of mucosa, and the drug’s enzymatic metabolism in the tissue. Additional work would be
needed to understand the possible implications in pharmacokinetics and our assumptions should be
verified in vivo on animal models.
4. Conclusions
This study aimed at the development and evaluation of a new solid dosage form, a sublingual
patch, in order to allow a massive release of FUR through the sublingual mucosa for hypertensive
management. A comprehensive set of characterizations have been performed showing that the
formulated mucoadhesive patch is flexible and resilient, although thinner than most patches produced
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for the purpose; its weight and drug content uniformity meet the Pharmacopoeia criteria. Moreover, it
shows good mucoadhesive properties and a high dissolution and drug release rate.
In particular, ex vivo studies have shown that the permeation of FUR released from film through
the sublingual mucosa occurs at a rate that is suitable to ensure the achievement of therapeutic
concentrations in the bloodstream. All the results gathered here suggest that the prepared matrix
film possesses adequate physio-chemical and drug release properties. Used as sublingual film, it can
enhance drug solubility and bioavailability, thus providing a better drug utilization and determining a
rapid onset of action. In addition to being able to circumvent the pitfalls of conventionally administered
systems, the proposed patch boasts a high level of patient acceptance.
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